All In Biotech

Drug Trial Radar · NCT06706427

Safety and Efficacy Study of NGGT001 in Bietti Crystalline Corneoretinal Dystrophy Subjects

A Phase I/II Study for Subretinal Injection of NGGT001 in Patients With Bietti Crystalline Corneoretinal Dystrophy

Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

12

Actual

Start

Mar 21, 2024

Primary completion

Nov 30, 2025

Study completion Sep 26, 2029

Sponsor

Sponsor type
Industry
First posted
Nov 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the safety, tolerability, and efficacy of subretinal injection of NGGT001 in patients with Bietti Crystalline Corneoretinal Dystrophy (BCD) and to recommend the optimal dosage for future clinical administration.

Conditions

  • Bietti Crystalline Corneoretinal Dystrophy

Interventions

  • NGGT001Biological

    Using a recombinant adeno-associated virus (AAV) vector to deliver the gene CYP4V2 via subretinal injection for the treatment of crystalline retinal degeneration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs) from baseline to 52 weeks.Time frame: 52 weeks
  2. Evaluate the improvement in BCVA compared to baseline at Week 12, 26 and 52.Time frame: Week 12, Week 26 and Week 52

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Southwest Hospital/Southwest Eye Hospital, Third Military Medical University (Army Medical University)

    Chongqing, Chongqing Municipality, China

  • Xiamen Eye Center of Xiamen University

    Xiamen, Fujian, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.